
Novartis to Expand US-Based Manufacturing and R&D with a $23B Investment Over the Next Five Years
Novartis announced a planned $23 billion investment over 5 years in US-based infrastructure, ensuring all key Novartis medicines for US patients will be made in the United States. This commitment enables Novartis to expand on its current manufacturing, …